ARTICLE | Company News
Crealta Pharmaceuticals, Savient deal
January 20, 2014 8:00 AM UTC
Crealta completed its acquisition of Savient's pharmaceutical portfolio, including gout drug Krystexxa pegloticase, for about $120.4 million (see BioCentury, Dec.16, 2013). ...